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Summary
This thesis describes one clinical and three endocrine studies with medroxy-
progesterone acetate (MPA) in postmenopausal \ryomen with advanced
breast cancer. In the clinical study, the therapeutic effect of MPA and tamo-
xifen are compared. In the endocrine studies, the effect of MPA on the pi-
tuitary adrenal axis as well as its mechanism are studied.
Chapter I is an introduction and gives a general view of hormonal therapy
in metastatic breast cancer. The frequent incidence of breast cancer is em-
phasized as well as the fact that two thirds of the patients eventually will re-
quire systemic palliative treatment. The choice between hormonal and cy-
tostatic therapy depends on a number ofconditions: age, disease-free inter-
val, tumor progression rate, predominant site and extent of metastases,
hormone receptor status and response to prior therapy. The various hormo-
nal modalities are successively discussed in historical sequence. On the one
hand there are the so-called ablative treatments: oophorectomy, adrenalec-
tomy and hypophysectomy. On the other hand the following additive thera-
pies nowadays are available: androgens, estrogens, progestins, corticoste-
roids, tamoxifen, aminoglutethimide and LHRH-analogues. Their mode of
action, effectiveness and side-effects are discussed. Finally the relation be-
tween dose and response is regarded. This relation does exist for the proges-
tins and possibly for estrogens and aminoglutethimide, but is not evident in
the other agents.
Chapter II describes the results of a prospective randomised multicentre
phase III trial comparing the response to treatment with oral high-dose
MPA and tamoxifen in previously untreated postmenopausal patients with
advanced breast cancer. MPA in a dose of 900 mg daily (300 mg t.i.d.)
yields a remission rate of 44"/" and appears to be at least as effective as
40 mg tamoxifen daily (20 mg b.i.d.) with a remission rate of 35"/o. The du-
ration of remission and the length of survival is not significantly different in
both treatment groups. In patients with predominant osseous metastases,
as well as in a group of patients over 70 years, MPA has a higher response
rate than tamoxifen. After disease progression, therapy was changed to the
other of the two drugs. As second treatment MPA appears to give a signifi-
cantly higher response than tamoxifen. MPA has more side effects, which
are sometimes severe. Consequently high-dose MPA will be reserved as the
second therapy after tamoxifen. However, in case of predominant osseous
metastases and in older patients it has to be considered as the initial treat-
ment.
In chapter III the effect of high-dose MPA on the pituitary-adrenal system
is described. Postmenopausal women with advanced breast cancer, treated
with MPA in a dose of 900 mg daily, are compared with (still) untreated
postmenopausal breast cancer patients. In most of the MPA-treated pa-
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tients the cortisol levels are lower. However, ACTH-levels are not clearly
increased, nor decreased, suggesting a simultaneous direct inhibition of
ACTH-release by MPA. The levels of the androgens androstenedione and
DHEA-S are suppressed to a similar extent as cortisol. Furthermore, a sig-
nificant fall of LH- and FSH-levels is observed, while prolactin and growth
hormone do not change. It seems reasonable to assume that high-dose
MPA has a direct, but incomplete suppressive effect on the adrenal func-
tion, combined with a negative effect on ACTH-release.
Chapter IV shows the endocrine effects of direct and indirect adrenal stimu-
lation in MPA-treated postmenopausal breast cancer patients. One group
of patients is treated with 900 mg MPA (300 mg t.i.d.) orally, a control
group is not (yet) treated. After direct adrenal stimulation with Synacthen
the stimulated cortisol levels in the MPA-group are lower than in the con-
trol group. The stimulated levels of androstenedione and 17-OH-progeste-
rone are also less high in the MPA-patients compared with the control pa-
tients, but to a lesser degree than the cortisol levels. Indirect adrenal stimu-
lation with metyrapone leads to a greater decrease of cortisol levels and a
greater increase of ACTH-levels in the MPA-group compared with the con-
trol group, but to a relatively small rise of 1l-desoxycortisol, androstene-
dione and 17-OH-progesterone. Thus there is an impaired adrenal response
to direct and indirect stimulation in MPA-treated patients. The higher
ACTH-levels, together with lower cortisol, after metyrapone in the MPA-
patients, indicate that a direct suppression of ACTH by MPA is not the only
cause of adrenal blockade. The small increase of 11-desoxycortisol, despite
a sufficient rise in endogenous ACTH-levels, suggests that this partial adre-
nal blockade is also located in the adrenals themselves. So the results of
both stimulation tests indicate a direct, but partial inhibitory effect of MPA
on the adrenals.
In chapter V the relation is discussed between different doses of MPA, the
plasma levels attained, and the extent of adrenal suppression. Apart from a
control group of patients, three other groups were formed, who received
doses MPA of 300 mg (group I), 600 mg (group II) and 900 mg (group III)
respectively. A significant difference in plasma concentration of MPA is
found between groups III and I. With a dose of 900 mg the median level of
MPA is higher than 100 ng/ml, which has been advised as a minimal level
for clinical effect. However, there appears to be a considerable variation in
individual MPA-levels within each group. Several explanations for this are
discussed. Significant differences in suppression of the adrenal steroids cor-
tisol, DHEA-S and androstenedione, as well as of oestrone, are found only
between the groups I and III, but not between the other groups. Cortisol le-
vels higher than 150 nmol/l appear to be a reliable indicator of insufficient
MPA-levels. However, low cortisol levels do not always indicate sufficient
MPA-levels. There seems to be a negative but weak correlation between
MPA-levels and the adrenal steroids, but not between MPA and oestrone
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levels. However, in the MPA-treated group a positive correlation between
androstenedione and oestrone is found. Suppression of oestrone, which is
the most important estrogen in postmenopausal women, may be responsi-
ble for the tumor-reducing effect of MPA in hormone dependent breast
cancer. Doses of 900 mg MPA result in a stronger adrenal suppression than
doses of 300 mg and thus lead to lower androstenedione and oestrone le-
vels. In this way the enhanced efficacy of high doses MPA in metastatic
breast cancer may be explained.
Conclusion. In postmenopausal patients with advanced breast cancer, oral
high-dose MPA has an efficacy comparable with that of tamoxifen. Gene-
rally MPA will be reserved as a second treatment after tamoxifen, because
it has more frequent side-effects and is more effective following tamoxifen,
while tamoxifen given after MPA has a poor therapeutic effect. MPA re-
sults in an incomplete direct adrenal suppression and has a negative effect
on ACTH release. High doses of MPA bring about higher plasma levels and
a greater adrenal suppression than lower doses. The fall ofandrostenedione
as the main source of postmenopausal oestrone may be a possible mecha-
nism for the enhanced effect of hieh doses of MPA in breast cancer.
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